Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DNTH

Dianthus Therapeutics Inc

Dec 12 • 04:00PM ET

42.13

+0.50 1.20 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM XBI VXF IWN SCHA VTWO AVSC IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.49	Insider Own	18.11%	Shs Outstand	42.85M	Perf Week	-4.81%
Market Cap	1.81B	Forward P/E	-	EPS next Y	-3.67	Insider Trans	-2.96%	Shs Float	32.54M	Perf Month	8.81%
Enterprise Value	1.41B	PEG	-	EPS next Q	-1.07	Inst Own	92.64%	Short Float	11.42%	Perf Quarter	13.74%
Income	-126.34M	P/S	586.48	EPS this Y	-46.35%	Inst Trans	3.50%	Short Ratio	5.64	Perf Half Y	130.09%
Sales	3.08M	P/B	3.30	EPS next Y	1.60%	ROA	-27.12%	Short Interest	3.71M	Perf YTD	93.26%
Book/sh	12.75	P/C	4.49	EPS next 5Y	-17.45%	ROE	-28.57%	52W High	45.46 -7.31%	Perf Year	69.81%
Cash/sh	9.39	P/FCF	-	EPS past 3/5Y	50.25% 40.14%	ROIC	-23.08%	52W Low	13.36 215.23%	Perf 3Y	114.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.71%	Volatility	4.34% 5.52%	Perf 5Y	-64.61%
Dividend TTM	-	EV/Sales	456.18	EPS Y/Y TTM	-39.78%	Oper. Margin	-4558.41%	ATR (14)	2.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.35	Sales Y/Y TTM	-42.64%	Profit Margin	-4104.78%	RSI (14)	54.38	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	17.35	EPS Q/Q	-32.30%	SMA20	-1.38%	Beta	1.56	Target Price	67.42
Payout	-	Debt/Eq	0.00	Sales Q/Q	-81.77%	SMA50	10.80%	Rel Volume	0.79	Prev Close	41.63
Employees	78	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	SMA200	60.90%	Avg Volume	658.88K	Price	42.13
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.82% -31.25%	Trades		Volume	520,151	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Initiated	Truist	Buy	$56
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21

Show Previous Ratings

Dec-05-25 06:35PM	Ashland, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-24-25 07:00AM	Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.38%
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.00%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Loading…
08:00AM	Dianthus Therapeutics to Participate in Four Investor Conferences During November (GlobeNewswire)
Oct-30-25 10:00AM	Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 03:30PM	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire)
Oct-16-25 07:00AM	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases (GlobeNewswire)
Oct-02-25 08:00AM	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting (GlobeNewswire) -5.14%
Sep-30-25 11:50AM	Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target (Insider Monkey)
Sep-19-25 03:26PM	Dianthus, Opendoor, and More Stocks See Action From Activist Investors (Barrons.com) -5.45%
Sep-11-25 04:07PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-09-25 10:35PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering (GlobeNewswire) +11.86% +6.55%
10:57AM	Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential (Insider Monkey)
07:15AM	Loading…
07:15AM	Dianthus to take gMG mAb to Phase III after mid-stage win (Clinical Trials Arena)
Sep-08-25 04:00PM	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering (GlobeNewswire) +20.00%
02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:21PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
07:00AM	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile (GlobeNewswire)
Sep-07-25 06:25PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-13-25 04:04PM	The Oncology Institute Announces Changes to Board of Directors (GlobeNewswire)
Aug-07-25 05:20PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.08%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-06-25 06:45PM	Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Loading…
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savitz Ryan	CFO & CBO	Dec 04 '25	Option Exercise	8.44	20,000	168,800	20,000	Dec 05 08:00 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Sale	45.18	20,000	903,600	0	Dec 05 08:00 PM
RYAN SAVITZ	Officer	Dec 04 '25	Proposed Sale	43.97	20,000	879,400		Dec 04 04:42 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Option Exercise	20.42	109,031	2,226,263	113,031	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Option Exercise	8.82	87,507	771,873	91,507	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Sale	38.14	109,031	4,158,442	4,000	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Sale	36.81	87,507	3,221,445	4,000	Nov 14 09:00 PM
SIMRAT RANDHAWA	Officer	Nov 13 '25	Proposed Sale	38.72	196,538	7,609,951		Nov 13 04:23 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Option Exercise	8.44	20,000	168,800	20,000	Sep 11 05:20 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Sale	35.00	20,000	700,000	0	Sep 11 05:20 PM
RYAN SAVITZ	Officer	Sep 09 '25	Proposed Sale	31.80	20,000	636,000		Sep 09 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNTH

Dianthus Therapeutics Inc

Upgrade your FINVIZ experience